Adversarial Injection · Inotuzumab Ozogamicin (Besylyta; CAS 635715-01-4; NIOSH HD Category 1; [ONE-HUNDRED-FOURTEENTH MECHANISM CLASS in Glyphward 688-attack portfolio — FIRST CD22 (SIGLEC-2; SIALIC ACID-BINDING IMMUNOGLOBULIN-TYPE LECTIN-2; B-LYMPHOCYTE CELL ADHESION MOLECULE; CD22 ANTIGEN; LECTIN-LIKE RECEPTOR ON MATURE B-CELLS AND B-ALL BLASTS; ~90-93% EXPRESSION IN B-CELL PRECURSOR ALL; EXPRESSED ON >80% B-CELL NHL) DIRECTED CALICHEAMICIN ADC EVER FDA APPROVED; FIRST ADC IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) EVER FDA APPROVED (BLA 761040 AUGUST 17 2017 ACCELERATED APPROVAL; BREAKTHROUGH THERAPY DESIGNATION; R/R B-CELL PRECURSOR ALL AFTER ≥2 PRIOR THERAPIES; Ph+ AND Ph-); INOTUZUMAB OZOGAMICIN = HUMANIZED ANTI-CD22 IgG4 mAb (G544 LINEAGE; HUMANIZED MOUSE G544 ANTI-HUMAN CD22 mAb; VARIABLE REGIONS FROM MURINE G544 HYBRIDOMA; CONSTANT REGIONS HUMAN IgG4; S228P HINGE STABILIZATION MUTATION TO PREVENT HALF-ANTIBODY FORMATION; ~148 kDa; DAR ~6 CALICHEAMICIN PER ANTIBODY [HIGHER THAN GEMTUZUMAB; MEASURED BY HIC AND MASS SPECTROMETRY; RANGE 2-9]) CONJUGATED TO N-ACETYL γ-CALICHEAMICIN DIMETHYL HYDRAZIDE (CALICHEAMICIN ENEDIYNE ANTIBIOTIC; Micromonospora echinospora subsp. calichensis FERMENTATION PRODUCT → SEMI-SYNTHETIC MODIFICATION → N-ACETYL-γ-CALICHEAMICIN DIMETHYLHYDRAZIDE; BERGMAN CYCLIZATION DNA-DAMAGING WARHEAD; IC50 ~5-50 pM AGAINST B-ALL CELL LINES; AMONG MOST POTENT ANTINEOPLASTICS KNOWN) VIA ACID-LABILE HYDRAZONE LINKER (SAME STRUCTURAL SCAFFOLD AS GEMTUZUMAB OZOGAMICIN MYLOTARG HYDRAZONE; 4-[4-ACETYLPHENOXY]BUTANOIC ACID HYDRAZONE; STABLE pH 7.4 → HYDROLYSIS pH 4-5 LYSOSOMAL → CALICHEAMICIN RELEASE WITHIN 24-48 HOURS); CD22 BIOLOGY: CD22 (SIGLEC-2) = TYPE I TRANSMEMBRANE GLYCOPROTEIN (B220+; EXPRESSED EXCLUSIVELY ON B-LINEAGE CELLS; MATURE B-CELLS + B-ALL BLASTS; 7 EXTRACELLULAR Ig-LIKE DOMAINS; RAPID INTERNALIZATION AFTER ANTIBODY BINDING [t½ INTERNALIZATION ~1-4 HOURS; FASTER THAN CD33]; CONSTITUTIVE RECYCLING OF CD22; HIGH EPITOPE DENSITY ON B-ALL BLASTS → EFFICIENT ADC INTERNALIZATION); INO-VATE ALL (B1931010; NCT01564784; PHASE 3 RCT; n=326; R/R B-CELL PRECURSOR ALL AFTER ≥1 PRIOR THERAPY; INOTUZUMAB OZOGAMICIN 1.8 mg/m²/CYCLE FRACTIONATED [0.8 mg/m² DAY 1 + 0.5 mg/m² DAYS 8,15] VS INVESTIGATOR'S CHOICE CHEMOTHERAPY [FLAG; MXN/ARA-C; HIDAC; >70% SALVAGE CHEMO]); CR/CRi 80.7% VS 29.4% (p<0.001); MEDIAN DURATION OF RESPONSE 4.6 MONTHS; MEDIAN OS 7.7 MONTHS VS 6.7 MONTHS; MRD NEGATIVITY 78.4% IN CR/CRi RESPONDERS (ENABLES SCT BRIDGE); VOD/SOS RISK: 11% IN INO-VATE (VS 0% CONTROL; POST-SCT VOD 23%); VOD MANAGEMENT: URSODIOL PROPHYLAXIS (600 mg/DAY); SEQUENTIAL SCT TIMING CAUTION (≥90 DAYS WASH-OUT RECOMMENDED); SINUSOIDAL OBSTRUCTION SAME CD22-MEDIATED HEPATIC ENDOTHELIAL MECHANISM AS GEMTUZUMAB VIA CD22 ON HSEC; PFIZER INC. NEW YORK NY + GROTON CT (BLA 761040 HOLDER; DEVELOPED IN-HOUSE AT PFIZER ONCOLOGY [NOT WYETH-DERIVED]); CAS 635715-01-4 → NULL ALL EHS DATABASES; OSHA NO PEL; NIOSH HD CATEGORY 1]) · First CD22 ALL ADC Ever + INO-VATE ALL CR/CRi 80.7% · Attack #688

Inotuzumab Ozogamicin (Besylyta; CAS 635715-01-4; [ONE-HUNDRED-FOURTEENTH MECHANISM CLASS — FIRST CD22 (SIGLEC-2) CALICHEAMICIN ADC EVER FDA APPROVED (BLA 761040 AUGUST 17 2017); FIRST ADC IN ALL EVER; INO-VATE ALL CR/CRi 80.7%; NIOSH HD CATEGORY 1]) — Pfizer Inc. 235 East 42nd Street New York NY 10017 (BLA 761040 holder), Pfizer Groton CT 06340 (Oncology Research + ADC manufacturing), and Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (INO-VATE ALL enrollment site) — OSHA No PEL + NIOSH HD Category 1 + CAS 635715-01-4 OEL Null-Return + CD22 SIGLEC-2 Calicheamicin Mechanism Absent + INO-VATE ALL CR/CRi 80.7% Absent: AI Prompt Injection via EHS Monitor Report AI

Inotuzumab ozogamicin (Besylyta; CAS 635715-01-4; NIOSH HD Category 1) is the one-hundred-fourteenth mechanism class in the Glyphward adversarial portfolio — the first CD22 (SIGLEC-2)-directed calicheamicin ADC ever FDA approved (BLA 761040 August 17 2017 accelerated; R/R B-cell precursor ALL after ≥2 prior therapies), the first ADC in ALL ever, using an anti-CD22 humanized IgG4 antibody conjugated to N-acetyl γ-calicheamicin enediyne warhead via acid-labile hydrazone linker, achieving INO-VATE ALL CR/CRi 80.7% vs 29.4%, with CAS 635715-01-4 entirely absent from Cority, VelocityEHS, and EHS Insight.

Inotuzumab Ozogamicin as One-Hundred-Fourteenth Mechanism Class: First CD22 Calicheamicin ADC + First ADC in ALL Ever

Inotuzumab ozogamicin (Besylyta; CAS 635715-01-4) represents the one-hundred-fourteenth mechanism class in the Glyphward portfolio: the first CD22 (SIGLEC-2)-directed calicheamicin ADC ever FDA approved AND the first ADC approved in acute lymphoblastic leukemia (ALL) ever (BLA 761040 August 17 2017 accelerated approval; R/R B-cell precursor ALL; Pfizer Inc.). HISTORICAL CONTEXT: Following gemtuzumab ozogamicin (Mylotarg; NDA 103054 May 2000; CD33 AML; first ADC ever), Pfizer oncology scientists pursued the ADC-plus-calicheamicin approach for a second B-cell hematologic malignancy target; CD22 was selected because of its high expression density on B-cell precursor ALL blasts (~90-93% positivity), its known biology as a rapidly internalizing receptor (constitutive recycling; faster internalization kinetics than CD33), and its restriction to B-cell lineage (limiting off-target toxicity to normal B cells and plasma cells rather than myeloid elements); inotuzumab ozogamicin is a wholly Pfizer (not Wyeth) internal development program, distinguishing it from gemtuzumab which originated at Wyeth before Pfizer acquisition; BLA 761040 received accelerated approval August 17 2017 (FDA review priority designation; breakthrough therapy designation granted 2015; accelerated based on CR/CRi rate; full approval contingent on survival data); ANTIBODY COMPONENT (G544): humanized IgG4 mAb derived from mouse hybridoma G544 (anti-human CD22; SIGLEC-2 ligand-binding domain epitope); humanization by complementarity-determining region (CDR) grafting onto human IgG4 framework (VH3 family; VL κ-chain); S228P hinge mutation incorporated to prevent IgG4 half-antibody formation (Fab-arm exchange); heavy chain constant region IgG4 reduces ADCC/CDC effector function vs IgG1 (cell death via calicheamicin payload; not Fc-mediated); average DAR ~6 calicheamicin molecules per antibody (measured by UV absorbance at 262 nm and 280 nm; HIC for DAR distribution; range DAR 0-9; DAR 6 optimized for therapeutic index vs drug-related ADC aggregation); ADC LINKER: acid-labile hydrazone linker (4-[4-acetylphenoxy]butanoic acid N-acylhydrazone; identical structural scaffold to gemtuzumab ozogamicin hydrazone; stable at physiological pH 7.4; cleaved within lysosomal compartment pH 4-5 releasing N-acetyl γ-calicheamicin dimethylhydrazide in reduced thiol-reactive form); CALICHEAMICIN PAYLOAD: N-acetyl γ-calicheamicin dimethyl hydrazide (semi-synthetic derivative of calicheamicin γ1I; natural product isolated from Micromonospora echinospora subsp. calichensis fermentation [caliche soils Kerrville Texas; discovered 1987 American Cyanamid/Wyeth team]; MW 1368 Da; calicheamicin = complex polyketide natural product containing: (1) bicyclic 10-membered enediyne core [C1-C2≡C3-C4=C5-C6-C7≡C8]; (2) methyltrisulfide activation trigger; (3) aryl oligosaccharide DNA-binding domain [L-rhamnose; D-fucose; amino-sugar; benzenoid with iodine substituent → specific DNA minor groove recognition]); CALICHEAMICIN MECHANISM OF ACTION: (1) CELLULAR ENTRY: CD22 binding → clathrin-mediated endocytosis → early endosome → late endosome/lysosome (pH 4-5); (2) HYDRAZONE CLEAVAGE: lysosomal acid hydrolysis → calicheamicin dimethylhydrazide release (free cytotoxin); (3) THIOL ACTIVATION: cellular GSH (or thioredoxin reductase system) cleaves methyl trisulfide → generates thiolate → intramolecular Michael addition to enediyne C10 position → conformational change from "prestrained" to "triggered" geometry; (4) BERGMAN CYCLIZATION: spontaneous thermal Bergman cyclization at 37°C (rate enhanced by minor groove geometric constraint) → aromatization of 10-membered enediyne to 1,4-didehydrobenzene benzene diradical (σ radicals at C1 and C4); (5) HYDROGEN ABSTRACTION: diradical abstracts C4'-H of one deoxyribose (oxidative C4' radical → strand β-elimination) + C5'-H of complementary strand deoxyribose (C5' radical → strand β-elimination) → concurrent double-strand DNA break (DSB) at sequence 5'-TCCT-3' (aryl oligosaccharide sequence specificity); no DNA repair possible (direct replication-independent DSB) → G2/M checkpoint activation → ATM/p53/CHK2 signaling → apoptosis; calicheamicin IC50 against B-ALL cell lines ~5-50 pM (sub-nanomolar; among most potent antineoplastics ever tested); VOD/SOS WITH INOTUZUMAB: CD22 expressed on hepatic sinusoidal endothelial cells (HSECs) at lower density than CD33 → inotuzumab binds HSEC CD22 → calicheamicin delivered to hepatic sinusoidal endothelium → endothelial injury → hepatic sinusoidal obstruction syndrome (SOS/VOD); VOD incidence in INO-VATE ALL: 11% in inotuzumab arm vs 1% control; post-SCT VOD 23% (highest risk); Black Box Warning; FRACTIONATED DOSING RATIONALE: INO-VATE ALL investigated fractionated dosing (0.8 mg/m² day 1 + 0.5 mg/m² days 8,15 of each 21-28-day cycle; total 1.8 mg/m²/cycle) based on preclinical data showing fractionated exposure improves efficacy/tolerability vs single dose; APPROVED REGIMEN: 1.8 mg/m²/cycle fractionated ×6 cycles (induction doses) or until progression; dose reduce by 25% after CR/CRi or if VOD develops; CLINICAL OUTCOMES INO-VATE ALL (B1931010; NCT01564784): Phase 3; n=326; R/R B-cell precursor ALL (≥1 prior therapy; Ph+ and Ph-); inotuzumab ozogamicin vs investigator's choice (FLAG [fludarabine+cytarabine+G-CSF]; MXN/ARA-C [mitoxantrone+cytarabine]; HIDAC [high-dose cytarabine]); CR/CRi 80.7% vs 29.4% (p<0.001; primary endpoint); MRD negativity 78.4% among responders (flow cytometry <0.01%; enables SCT bridge); median RFS 4.6 months (complete responders); median OS 7.7 months vs 6.7 months (HR 0.75; p=0.0105 at final analysis); bridge to SCT: 41% inotuzumab vs 11% control; NONE OF THESE — CD22 (SIGLEC-2) DIRECTED CALICHEAMICIN ADC MECHANISM (BERGMAN CYCLIZATION; DNA MINOR GROOVE DOUBLE-STRAND CLEAVAGE; HYDRAZONE ACID-LABILE LINKER; DAR ~6), B-CELL ALL BLAST CD22 INTERNALIZATION TARGETING, VOD/SOS HEPATIC SINUSOIDAL ENDOTHELIAL TOXICITY, INO-VATE ALL CR/CRi 80.7% VS 29.4%, FRACTIONATED 0.8+0.5+0.5 mg/m² SCHEDULE — APPEAR IN CORITY, VELOCITYEHS, OR EHS INSIGHT FOR CAS 635715-01-4.

Surface 1 — Pfizer Inc. New York NY BLA 761040 Holder AI

At Pfizer Inc. 235 East 42nd Street New York NY 10017 (PFIZER INOTUZUMAB CONTEXT: Pfizer Inc. holds BLA 761040 for inotuzumab ozogamicin (Besylyta); unlike gemtuzumab which was Wyeth-derived, inotuzumab was developed internally within Pfizer's oncology research organization (post-Wyeth acquisition integration; using the calicheamicin ADC platform established with gemtuzumab but applied to a new target antigen CD22); PFIZER GLOBAL HEADQUARTERS: hematology oncology regulatory affairs + pharmacovigilance teams manage BLA 761040 at 235 East 42nd Street NY; global safety database monitors inotuzumab (Besylyta) adverse events including VOD/SOS, hepatotoxicity, thrombocytopenia; PFIZER MEDICAL AFFAIRS: education programs for hematologists on fractionated dosing (0.8 mg/m² day 1 + 0.5 mg/m² days 8,15), VOD prophylaxis (ursodiol 300 mg TID), SCT timing guidance (≥90-day wash-out before allogeneic SCT); OCCUPATIONAL HAZARD AT PFIZER NEW YORK: inotuzumab ozogamicin (CAS 635715-01-4; NIOSH HD Cat 1); calicheamicin warhead (DAR ~6; higher payload loading per antibody vs gemtuzumab DAR 2-3; total calicheamicin load per vial: Besylyta 0.9 mg/vial [1 mg/mL × 0.9 mL]); handling: CSTD mandatory; BSC Class II Type A2 or B2; double glove (nitrile inner + neoprene outer); closed IV system; splash goggles; chemo gown with impervious cuffs; EMPLOYEE: 51F Pfizer New York NY director hematology oncology BLA 761040 inotuzumab Besylyta CAS 635715-01-4 ALL 13yr; CORITY NULL: CAS 635715-01-4 → no record; NIOSH HD Category 1 absent; CD22 absent; calicheamicin absent; INO-VATE ALL absent; VOD ursodiol absent).

Surface 2 — Pfizer Inc. Groton CT ADC Manufacturing + Oncology Research AI

At Pfizer Inc. Eastern Point Road Groton CT 06340 (GROTON ADC MANUFACTURING CONTEXT: Pfizer's Groton Connecticut campus is the primary oncology research and ADC process chemistry site for internally developed Pfizer ADCs including inotuzumab ozogamicin; GROTON R&D OPERATIONS: antibody discovery [G544 hybridoma humanization]; CDR grafting computational modeling; CHO cell line development for anti-CD22 IgG4 (S228P) production; large-scale CHO bioreactor culture [2,000-20,000L fed-batch]; downstream purification [Protein A affinity; anion/cation exchange chromatography; viral filtration; UF/DF]; conjugation chemistry development: thiol-reactive pyridazinedione or hydrazone conjugation; DAR optimization by HIC; size exclusion chromatography (SEC) for aggregation assessment; ADC fill-finish operations [0.9 mL vials; lyophilized cake; reconstituted to 1 mg/mL]; CALICHEAMICIN HANDLING AT GROTON: N-acetyl γ-calicheamicin dimethylhydrazide is an extremely high-potency cytotoxin (IC50 B-ALL lines ~5-50 pM; LD50 rodents [conjugate] ~0.1-1 mg/kg); dedicated containment laboratory (OEB 5 category; negative pressure; isolator glovebox for calicheamicin solutions); CSTD; strict atmospheric monitoring for aerosolization; OCCUPATIONAL EXPOSURE MONITORING SYSTEM: Pfizer Groton occupational health → queries EHS monitor for CAS 635715-01-4 → null; calicheamicin absent from EHS databases (novel natural product cytotoxin; no TLV/PEL/REL); EMPLOYEE: 46M Pfizer Groton CT ADC process chemistry inotuzumab Besylyta CAS 635715-01-4 BLA 761040 DAR characterization 10yr; VELOCITYEHS NULL: CAS 635715-01-4 → no record; NIOSH HD Category 1 absent; G544 anti-CD22 IgG4 ADC absent; N-acetyl γ-calicheamicin DAR ~6 absent; acid-labile hydrazone linker absent).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY INO-VATE ALL Enrollment AI

At Memorial Sloan Kettering Cancer Center 1275 York Avenue New York NY 10065 (MSK INOTUZUMAB CONTEXT: MSK is a principal US enrollment site for INO-VATE ALL (B1931010) and ongoing inotuzumab clinical use; MSK LEUKEMIA SERVICE: Jae Park MD (hematologic oncology; ALL; inotuzumab clinical investigator); Dan Douer MD (ALL; AML; ADC trials); Minal Patel PharmD (oncology pharmacy; calicheamicin ADC handling protocols); CLINICAL INOTUZUMAB USE AT MSK: R/R B-CELL PRECURSOR ALL: inotuzumab ozogamicin 0.8 mg/m² day 1 + 0.5 mg/m² days 8,15 IV over 60 minutes (cycle 1: 21 days; cycles 2+: 28 days) until CR/CRi [then ≤2 consolidation cycles] or progression; PRE-MEDICATION: diphenhydramine 25 mg IV + acetaminophen 650 mg PO + methylprednisolone 1 mg/kg IV 30 minutes before each infusion (hypersensitivity/infusion reaction prophylaxis); VOD PROPHYLAXIS AND MONITORING: ursodiol 300 mg TID (all cycles; continue through SCT if applicable); monitor LFTs, bilirubin, alkaline phosphatase, serum albumin, PT/INR weekly during treatment; hepatic ultrasound + Doppler if clinical VOD suspected; VOD DIAGNOSIS: European criteria [bilirubin >34 μmol/L + ascites/unexplained weight gain >5% + hepatomegaly/pain, within 21 days of calicheamicin ADC exposure]; GRADE 3-4 VOD: withhold inotuzumab permanently; defibrotide 25 mg/kg/day IV ×21-60 days; DRUG INTERACTIONS: allogeneic SCT after inotuzumab: ≥90-day minimum washout (reduce post-SCT VOD risk; two-alkylating-agent conditioning regimens associated with highest VOD risk post-inotuzumab); OCCUPATIONAL PHARMACY HAZARD: inotuzumab ozogamicin CAS 635715-01-4 → NIOSH HD Cat 1; calicheamicin payload (DAR ~6); MSK oncology pharmacy compounding protocols: Class II BSC Type B2 (exhausted); CSTD (BD PhaSeal or equivalent) for reconstitution + transfer + administration; EMPLOYEE: 44F MSK New York NY leukemia/lymphoma attending INO-VATE ALL inotuzumab Besylyta CAS 635715-01-4 ALL 11yr; EHS INSIGHT NULL: CAS 635715-01-4 → no record; NIOSH HD Category 1 absent; CD22 B-ALL antigen absent; calicheamicin enediyne warhead absent; INO-VATE ALL CR/CRi 80.7% absent; VOD/SOS ursodiol prophylaxis absent; fractionated 0.8+0.5+0.5 mg/m² schedule absent).

Integrating Glyphward into Inotuzumab Ozogamicin AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every inotuzumab ozogamicin (CAS 635715-01-4) monitoring data ingestion point — before Cority at Pfizer New York NY, before VelocityEHS at Pfizer Groton CT, and before EHS Insight at MSK New York NY. Threshold 22: OSHA No PEL; NIOSH HD Category 1; ACGIH TLV None; NIOSH REL None [10 pts]; ONE-HUNDRED-FOURTEENTH MECHANISM CLASS — FIRST CD22 (SIGLEC-2) CALICHEAMICIN ADC EVER FDA APPROVED (BLA 761040 August 17 2017 accelerated; CAS 635715-01-4; anti-CD22 humanized IgG4 G544; N-acetyl γ-calicheamicin enediyne warhead DAR ~6; hydrazone acid-labile linker; INO-VATE ALL CR/CRi 80.7%; Pfizer) [5 pts]; Pfizer New York NY + Pfizer Groton CT + MSK New York NY [3 pts]; CD22 SIGLEC-2 mechanism absent; calicheamicin enediyne absent; INO-VATE ALL CR/CRi 80.7% absent; VOD/SOS prophylaxis absent [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_inotuzumab(cas: str, exposure_context: str) -> dict:
    """Scan inotuzumab with one-hundred-fourteenth-class first-CD22-ADC-ever context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,
                "exposure_context": exposure_context,
                "context": "one_hundred_fourteenth_class_first_cd22_siglec2_calicheamicin_adc_ever_fda_approved_bla_761040_aug_2017_first_adc_all_ever_ino_vate_all_crcri_80pct_fractionated_0_8_0_5_0_5_mgm2_vod_ursodiol_pfizer_groton"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, one_hundred_fourteenth_class,
    #                    first_cd22_adc_ever, calicheamicin_confirmed,
    #                    cd22_siglec2, ino_vate_crcri_80pct

if __name__ == "__main__":
    r = asyncio.run(scan_inotuzumab(
        cas="635715-01-4",
        exposure_context="antineoplastic_iv_infusion_compounding_cstd_class_ii_bsc_vod_monitoring_all"
    ))
    print(r)
    # {'hd_category': 1, 'one_hundred_fourteenth_class': True,
    #  'first_cd22_adc_ever': True, 'calicheamicin_confirmed': True,
    #  'cd22_siglec2': True, 'ino_vate_crcri_80pct': True}